Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Future of PD-1/PD-L1 axis modulation for the treatment of triple-negative breast cancer
Maryam Nakhjavani, Sarah Shigdar
Pharmacological Research (2021) Vol. 175, pp. 106019-106019
Closed Access | Times Cited: 31

Showing 1-25 of 31 citing articles:

Epigenetic modulations in triple-negative breast cancer: Therapeutic implications for tumor microenvironment
Linlin Zhou, Danny Yu
Pharmacological Research (2024) Vol. 204, pp. 107205-107205
Open Access | Times Cited: 15
Nectin-4-targeted immunoSPECT/CT imaging and photothermal therapy of triple-negative breast cancer
Fuqiang Shao, Zhidi Pan, Yu Long, et al.
Journal of Nanobiotechnology (2022) Vol. 20, Iss. 1
Open Access | Times Cited: 40
T cell-derived exosomes in tumor immune modulation and immunotherapy
Qiujun Zhou, Shenyu Wei, Hui Wang, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 24
Recent progress, perspectives, and issues of engineered PD-L1 regulation nano-system to better cure tumor: A review
Zaigang Zhou, Haoxiang Wang, Jie Li, et al.
International Journal of Biological Macromolecules (2023) Vol. 254, pp. 127911-127911
Closed Access | Times Cited: 22
The opportunities and challenges of using PD-1/PD-L1 inhibitors for leukemia treatment
Mengdan Xu, Shenglong Li
Cancer Letters (2024) Vol. 593, pp. 216969-216969
Closed Access | Times Cited: 11
Application of biomimetic nanovaccines in cancer immunotherapy: A useful strategy to help combat immunotherapy resistance
Zhijie Xu, Zhou Hai-yan, Tongfei Li, et al.
Drug Resistance Updates (2024) Vol. 75, pp. 101098-101098
Closed Access | Times Cited: 9
The combination of flaxseed lignans and PD-1/ PD-L1 inhibitor inhibits breast cancer growth via modulating gut microbiome and host immunity
Hao Wu, J.F. Liu, Xinghua Zhang, et al.
Drug Resistance Updates (2025) Vol. 80, pp. 101222-101222
Open Access | Times Cited: 1
Aptamer-Based Strategies to Boost Immunotherapy in TNBC
Lisa Agnello, Annachiara d’Argenio, Roberto Nilo, et al.
Cancers (2023) Vol. 15, Iss. 7, pp. 2010-2010
Open Access | Times Cited: 14
PD-L1 blockade peptide-functionalized NaGdF4 nanodots for efficient magnetic resonance imaging-guided immunotherapy for breast cancer
Zhenzhen Hu, Yunkai Bao, Xiaodong Li, et al.
RSC Advances (2025) Vol. 15, Iss. 12, pp. 9027-9033
Open Access
Triple-negative breast cancer brain metastasis: An update on druggable targets, current clinical trials, and future treatment options
Maryam Nakhjavani, Rasika M. Samarasinghe, Sarah Shigdar
Drug Discovery Today (2022) Vol. 27, Iss. 5, pp. 1298-1314
Closed Access | Times Cited: 18
Huaier-induced suppression of cancer-associated fibroblasts confers immunotherapeutic sensitivity in triple-negative breast cancer
Chen Li, Xiaolong Wang, Luyao Xing, et al.
Phytomedicine (2024) Vol. 135, pp. 156051-156051
Open Access | Times Cited: 3
Unravelling the Glioblastoma Tumour Microenvironment: Can Aptamer Targeted Delivery Become Successful in Treating Brain Cancers?
Breanna Giles, Maryam Nakhjavani, Andrew Wiesa, et al.
Cancers (2023) Vol. 15, Iss. 17, pp. 4376-4376
Open Access | Times Cited: 8
Modelling of mass transport and distribution of aptamer in blood-brain barrier for tumour therapy and cancer treatment
Mohsen Sarafraz, Maryam Nakhjavani, Sarah Shigdar, et al.
European Journal of Pharmaceutics and Biopharmaceutics (2022) Vol. 173, pp. 121-131
Closed Access | Times Cited: 13
Immunotherapy: Review of the Existing Evidence and Challenges in Breast Cancer
Yun Hu, Yan Li, Zhangcheng Yao, et al.
Cancers (2023) Vol. 15, Iss. 3, pp. 563-563
Open Access | Times Cited: 7
Impact of Brain Organoid-Derived sEVs on Metastatic Adaptation and Invasion of Breast Carcinoma Cells through a Microphysiological System
Hojjatollah Nazari, Ann‐Na Cho, Dale M. Goss, et al.
Lab on a Chip (2024) Vol. 24, Iss. 14, pp. 3434-3455
Closed Access | Times Cited: 2
Gold nanorods with iron oxide dual-modal bioprobes in SERS-MRI enable accurate programmed cell death ligand-1 expression detection in triple-negative breast cancer
Ting Pan, Dinghu Zhang, Xiaoxia Wu, et al.
APL Bioengineering (2023) Vol. 7, Iss. 2
Open Access | Times Cited: 6
Cytotoxic effects of aptamer-doxorubicin conjugates in an ovarian cancer cell line
Justin Henri, Maryam Nakhjavani, Scott McCoombe, et al.
Biochimie (2022) Vol. 204, pp. 108-117
Closed Access | Times Cited: 9
Unravelling the Glioblastoma Tumour Microenvironment: Can Aptamer Targeted Delivery Emerge Successful in Treating Brain Cancers?
Breanna Giles, Maryam Nakhjavani, Andrew Wiesa, et al.
(2023)
Open Access | Times Cited: 5
Natural Blockers of PD-1/PD-L1 Interaction for the Immunotherapy of Triple-Negative Breast Cancer-Brain Metastasis
Maryam Nakhjavani, Sarah Shigdar
Cancers (2022) Vol. 14, Iss. 24, pp. 6258-6258
Open Access | Times Cited: 7
Immune checkpoints expression patterns in early-stage triple-negative breast cancer predict prognosis and remodel the tumor immune microenvironment
Jinguo Zhang, Hongwei Jin, Shuaikang Pan, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 3
Amino acids and their roles in tumor immunotherapy of breast cancer
Hongzhuo Xia, Jianyu Zhu, Zhuomeng Zheng, et al.
The Journal of Gene Medicine (2023) Vol. 26, Iss. 1
Closed Access | Times Cited: 2
An overview of the therapeutic strategies for neoplastic meningitis due to breast cancer: when and why?
Mainak Bardhan, Debankur Dey, Vinay Suresh, et al.
Expert Review of Neurotherapeutics (2023) Vol. 24, Iss. 1, pp. 77-103
Closed Access | Times Cited: 2
Development of a novel prognostic signature based on single‐cell combined bulk RNA analysis in breast cancer
Ying Xiao, Ge Hu, Ning Xie, et al.
The Journal of Gene Medicine (2024) Vol. 26, Iss. 2
Closed Access
LCP1 is a potential prognostic biomarker and correlates with immune infiltration in triple negative breast cancer
Shuaikang Pan, Mengting Wan, Hongwei Jin, et al.
Research Square (Research Square) (2024)
Open Access
LCP1 correlates with immune infiltration: a prognostic marker for triple-negative breast cancer
Shuaikang Pan, Mengting Wan, Hongwei Jin, et al.
BMC Immunology (2024) Vol. 25, Iss. 1
Open Access
Page 1 - Next Page

Scroll to top